The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation. In this article, leadership from disruptive new biopharmaceutical CDMO Wheeler Bio discuss the benefits of forward-looking digitalization and collaboration in the industry. Following Pharma 4.0 principles, Wheeler Bio is working to integrate hardware, software, and biology to deliver a new tier of biomanufacturing quality, clinical timelines, and data transparency for emerging biotech companies.
